NLS Pharmaceutics AG Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2022	2021	2020	2019	2018
Market Capitalization	5	23	13	-	-	-
Market Cap Growth	-	71.28%	-	-	-	-
Enterprise Value	4	14	8	2	1	7
PE Ratio	-2.31	-1.39	-1.12	-	-	-
PB Ratio	-8.32	6.99	24.70	-	-	-
P/FCF Ratio	-2.64	-1.65	-0.89	-	-	-
P/OCF Ratio	-2.64	-1.65	-0.90	-	-	-
EV/EBITDA Ratio	-2.21	-0.85	-0.67	-0.76	-0.13	-1.74
EV/EBIT Ratio	-2.21	-0.85	-0.67	-0.76	-0.13	-1.74
EV/FCF Ratio	-2.52	-1.01	-0.53	-2.73	-3.27	-2.59
Debt / Equity Ratio	-	-	-	-0.23	-0.14	-0.80
Debt / EBITDA Ratio	-	-	-	-0.79	-0.18	-1.75
Debt / FCF Ratio	-	-	-	-2.86	-4.43	-2.60
Quick Ratio	0.42	2.66	2.26	0.01	0.05	0.00
Current Ratio	0.58	2.75	2.38	0.03	0.10	0.04
Interest Coverage	-167.46	-162.54	-174.33	-11.24	-5.65	-3.74
Return on Equity (ROE)	371.40%	-862.90%	283.00%	37.80%	72.70%	-
Return on Assets (ROA)	-714.70%	-219.30%	-342.50%	-299.90%	-1293.80%	-
Return on Capital (ROIC)	334.60%	-471.90%	-2186.74%	33.33%	78.76%	200.46%
Earnings Yield	-283.30%	-71.90%	-89.18%	-	-	-
FCF Yield	-247.46%	-60.49%	-111.79%	-	-	-
Buyback Yield / Dilution	-244.88%	-65.38%	-71.00%	-1.75%	-9.62%	-
Total Shareholder Return	-244.88%	-65.38%	-71.00%	-1.75%	-9.62%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).